2024
Enrollment in High-Deductible Health Plans and Incident Diabetes Complications
McCoy R, Swarna K, Jiang D, Van Houten H, Chen J, Davis E, Herrin J. Enrollment in High-Deductible Health Plans and Incident Diabetes Complications. JAMA Network Open 2024, 7: e243394. PMID: 38517436, PMCID: PMC10960199, DOI: 10.1001/jamanetworkopen.2024.3394.Peer-Reviewed Original ResearchConceptsHigh-deductible health plansHealth plansChronic disease managementOdds of myocardial infarctionLower-extremity complicationsMixed-effects logistic regression modelsOut-of-pocket costsAssociated with increased oddsDiabetic complicationsInverse propensity score weightingLogistic regression modelsCardiovascular risk factorsEmployer-sponsored health plansDiabetes careRetrospective cohort studyUS adultsPropensity score weightingPotential selection biasMain OutcomesCohort studyBaseline yearIncident complicationsDisease managementMixed-effectsPotential harm
2020
Risk of Systemic Adverse Events after Intravitreal Bevacizumab, Ranibizumab, and Aflibercept in Routine Clinical Practice
Maloney MH, Payne SR, Herrin J, Sangaralingham LR, Shah ND, Barkmeier AJ. Risk of Systemic Adverse Events after Intravitreal Bevacizumab, Ranibizumab, and Aflibercept in Routine Clinical Practice. Ophthalmology 2020, 128: 417-424. PMID: 32781110, DOI: 10.1016/j.ophtha.2020.07.062.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenesis InhibitorsBevacizumabCerebrovascular DisordersDrug-Related Side Effects and Adverse ReactionsFemaleHemorrhageHospitalizationHumansIntravitreal InjectionsMaleMyocardial InfarctionRanibizumabReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsRetinal DiseasesRetrospective StudiesRisk AssessmentVascular Endothelial Growth Factor AConceptsNeovascular age-related macular degenerationRetinal venous occlusive diseaseDiabetic retinal diseaseSystemic serious adverse eventsAnti-VEGF injectionsAnti-VEGF agentsMajor bleedingAcute myocardial infarctionCause hospitalizationCerebrovascular diseaseRoutine clinical practiceMyocardial infarctionIntravitreal bevacizumabTreatment initiationAdverse eventsPropensity score-weighted Cox proportional hazards modelClinical practiceLarge U.S. administrative claims databaseRisk of MICox proportional hazards modelU.S. administrative claims databaseAge-related macular degenerationRisk-adjusted effectSystemic safety profileRetrospective cohort study